FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377208533> ?p ?o ?g. }

• W4377208533 endingPage "104766" @default.
• W4377208533 startingPage "104766" @default.
• W4377208533 abstract "BackgroundOlder age and longer disease duration (DD) may impact the effectiveness of disease-modifying therapies in patients with multiple sclerosis (MS). Siponimod is a sphingosine 1-phosphate receptor modulator approved for the treatment of active secondary progressive MS (SPMS) in many countries. The pivotal phase 3 EXPAND study examined siponimod versus placebo in a broad SPMS population with both active and non-active disease. In this population, siponimod demonstrated significant efficacy, including a reduction in the risk of 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP). Benefits of siponimod were also observed across age and DD subgroups in the overall EXPAND population. Herein we sought to assess the clinical impact of siponimod across age and disease duration subgroups, specifically in participants with active SPMS.MethodsThis study is a post hoc analysis of a subgroup of EXPAND participants with active SPMS (≥ 1 relapse in the 2 years before the study and/or ≥ 1 T1 gadolinium-enhancing magnetic resonance imaging lesion at baseline) receiving oral siponimod (2 mg/day) or placebo during EXPAND. Data were analyzed for participant subgroups stratified by age at baseline (primary cut-off: < 45 year ≥ 45 years; and secondary cut-off: < 50 years or ≥ 50 years) and by DD at baseline (< 16 years or ≥ 16 years). Efficacy endpoints were 3mCDP and 6mCDP. Safety assessments included adverse events (AEs), serious AEs, and AEs leading to treatment discontinuation.ResultsData from 779 participants with active SPMS were analyzed. All age and DD subgroups had 31–38% (3mCDP) and 27–43% (6mCDP) risk reductions with siponimod versus placebo. Compared with placebo, siponimod significantly reduced the risk of 3mCDP in participants aged ≥ 45 years (hazard ratio [HR]: 0.68; 95% confidence interval [CI]: 0.48–0.97), < 50 years (HR: 0.69; 95% CI: 0.49–0.98), ≥ 50 years (HR: 0.62; 95% CI: 0.40–0.96), and in participants with < 16 years DD (HR: 0.68; 95% CI: 0.47–0.98). The risk of 6mCDP was significantly reduced with siponimod versus placebo for participants aged < 45 years (HR: 0.60; 95% CI: 0.38–0.96), ≥ 45 years (HR: 0.67; 95% CI: 0.45–0.99), < 50 years (HR: 0.62; 95% CI: 0.43–0.90), and in participants with < 16 years DD (HR: 0.57; 95% CI: 0.38–0.87). Increasing age or longer MS duration did not appear to increase the risk of AEs, with an observed safety profile that remained consistent with the overall active SPMS and overall SPMS populations in EXPAND.ConclusionsIn participants with active SPMS, treatment with siponimod demonstrated a statistically significant reduction in the risk of 3mCDP and 6mCDP compared with placebo. Although not every outcome reached statistical significance in the subgroup analyses (possibly a consequence of small sample sizes), benefits of siponimod were seen across a spectrum of ages and DD. Siponimod was generally well tolerated by participants with active SPMS, regardless of baseline age and DD, and AE profiles were broadly similar to those observed in the overall EXPAND population." @default.
• W4377208533 created "2023-05-22" @default.
• W4377208533 creator A5012376027 @default.
• W4377208533 creator A5020903163 @default.
• W4377208533 creator A5025501697 @default.
• W4377208533 creator A5029734617 @default.
• W4377208533 creator A5035194673 @default.
• W4377208533 creator A5047368502 @default.
• W4377208533 creator A5052915346 @default.
• W4377208533 creator A5067317369 @default.
• W4377208533 creator A5076130466 @default.
• W4377208533 creator A5077310868 @default.
• W4377208533 date "2023-07-01" @default.
• W4377208533 modified "2023-10-16" @default.
• W4377208533 title "Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study" @default.
• W4377208533 cites W1490521057 @default.
• W4377208533 cites W2013481339 @default.
• W4377208533 cites W2303047345 @default.
• W4377208533 cites W2574627421 @default.
• W4377208533 cites W2767362256 @default.
• W4377208533 cites W2790816436 @default.
• W4377208533 cites W2793526309 @default.
• W4377208533 cites W2795937082 @default.
• W4377208533 cites W3097683738 @default.
• W4377208533 cites W3111909225 @default.
• W4377208533 cites W3121899751 @default.
• W4377208533 cites W3165109500 @default.
• W4377208533 cites W4210933644 @default.
• W4377208533 cites W4220926696 @default.
• W4377208533 cites W4226197684 @default.
• W4377208533 cites W4281650051 @default.
• W4377208533 doi "https://doi.org/10.1016/j.msard.2023.104766" @default.
• W4377208533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37245350" @default.
• W4377208533 hasPublicationYear "2023" @default.
• W4377208533 type Work @default.
• W4377208533 citedByCount "1" @default.
• W4377208533 countsByYear W43772085332023 @default.
• W4377208533 crossrefType "journal-article" @default.
• W4377208533 hasAuthorship W4377208533A5012376027 @default.
• W4377208533 hasAuthorship W4377208533A5020903163 @default.
• W4377208533 hasAuthorship W4377208533A5025501697 @default.
• W4377208533 hasAuthorship W4377208533A5029734617 @default.
• W4377208533 hasAuthorship W4377208533A5035194673 @default.
• W4377208533 hasAuthorship W4377208533A5047368502 @default.
• W4377208533 hasAuthorship W4377208533A5052915346 @default.
• W4377208533 hasAuthorship W4377208533A5067317369 @default.
• W4377208533 hasAuthorship W4377208533A5076130466 @default.
• W4377208533 hasAuthorship W4377208533A5077310868 @default.
• W4377208533 hasBestOaLocation W43772085331 @default.
• W4377208533 hasConcept C126322002 @default.
• W4377208533 hasConcept C142724271 @default.
• W4377208533 hasConcept C143998085 @default.
• W4377208533 hasConcept C197934379 @default.
• W4377208533 hasConcept C204787440 @default.
• W4377208533 hasConcept C27081682 @default.
• W4377208533 hasConcept C2778715236 @default.
• W4377208533 hasConcept C2908647359 @default.
• W4377208533 hasConcept C535046627 @default.
• W4377208533 hasConcept C67761136 @default.
• W4377208533 hasConcept C71924100 @default.
• W4377208533 hasConcept C99454951 @default.
• W4377208533 hasConceptScore W4377208533C126322002 @default.
• W4377208533 hasConceptScore W4377208533C142724271 @default.
• W4377208533 hasConceptScore W4377208533C143998085 @default.
• W4377208533 hasConceptScore W4377208533C197934379 @default.
• W4377208533 hasConceptScore W4377208533C204787440 @default.
• W4377208533 hasConceptScore W4377208533C27081682 @default.
• W4377208533 hasConceptScore W4377208533C2778715236 @default.
• W4377208533 hasConceptScore W4377208533C2908647359 @default.
• W4377208533 hasConceptScore W4377208533C535046627 @default.
• W4377208533 hasConceptScore W4377208533C67761136 @default.
• W4377208533 hasConceptScore W4377208533C71924100 @default.
• W4377208533 hasConceptScore W4377208533C99454951 @default.
• W4377208533 hasFunder F4320310388 @default.
• W4377208533 hasLocation W43772085331 @default.
• W4377208533 hasLocation W43772085332 @default.
• W4377208533 hasOpenAccess W4377208533 @default.
• W4377208533 hasPrimaryLocation W43772085331 @default.
• W4377208533 hasRelatedWork W1986043820 @default.
• W4377208533 hasRelatedWork W2029872562 @default.
• W4377208533 hasRelatedWork W2063767287 @default.
• W4377208533 hasRelatedWork W2064879719 @default.
• W4377208533 hasRelatedWork W2085830368 @default.
• W4377208533 hasRelatedWork W2509102166 @default.
• W4377208533 hasRelatedWork W3023502736 @default.
• W4377208533 hasRelatedWork W3159907377 @default.
• W4377208533 hasRelatedWork W4230537958 @default.
• W4377208533 hasRelatedWork W4306722605 @default.
• W4377208533 hasVolume "75" @default.
• W4377208533 isParatext "false" @default.
• W4377208533 isRetracted "false" @default.
• W4377208533 workType "article" @default.